Acute promyelocytic leukemia: From highly fatal to highly curable

Blood

Volumn 111, Issue 5, 2008, Pages 2505-2515

  Wang, Zhen Yi ^a   Chen, Zhu ^a,b,c  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Shanghai Jiao Tong University   (China)

^c BEIJING HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; ANTILEUKEMIC AGENT; ARSENIC TRIOXIDE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYTARABINE; DAUNORUBICIN; FLT3 LIGAND; GAMMA INTERFERON; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; ISOTRETINOIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HUM195; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; STRESS ACTIVATED PROTEIN KINASE; SU 11657; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ORGANOARSENIC DERIVATIVE; OXIDE;

BONE MARROW DEPRESSION; CANCER REGRESSION; CHINA; CHROMOSOME 15; CHROMOSOME 17; DISEASE FREE SURVIVAL; GENE; HUMAN; LYMPHOCYTE DIFFERENTIATION; OUTCOMES RESEARCH; PML GENE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RARALPHA GENE; RECIPROCAL CHROMOSOME TRANSLOCATION; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT; ANIMAL; CHEMISTRY; HISTORY;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; HISTORY, 20TH CENTURY; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; OXIDES; TRETINOIN;

EID: 41949111045     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-07-102798     Document Type: Review

References (111)

1. Hillestad LK. Acute promyelocytic leukemia. Acta Med Scand. 1957;159:189-194.
2. Bernard J, Mathe G, Boulay J, Ceoard B, Chome J. Acute promyelocytic leukemia: a study made on 20 cases. Schweiz Med Wochenschr. 1959;89:604-608.
3. Bernard J, Weil M, Boiron M, et al. Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood. 1973;41:489-496.
4. Cunningham I, Gee TS, Reich LM, et al. Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood. 1989;73:1116-1122.
5. Sanz MA, Jarque I, Martin G, et al. Acute promyelocytic leukemia: therapy results and prognostic factors. Cancer. 1988;61:7-13.
6. Fenaux P, Wang ZZ, Degos L. Treatment of acute promyelocytic leukemia by retinoids. Curr Top Microbiol Immunol. 2007;313:101-128.
7. Pierce GB Jr, Verney EL. An in vitro and in vivo study of differentiation in teratocarcinoma. Cancer. 1961;14:1017-1029.
8. Friend C, Scher W, Holland JG, Sato T. Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation bydimethyl sulfoxide. Proc Natl Acad Sci U S A. 1971;68:378-382.
9. Schubert D, Humphreys S, Jacob F, de Vitry F. Induced differentiation of a neuroblastoma. Dev Biol. 1971;25:514-546.
10. Sachs L. Control of normal cell differentiation and the phenotypic reversion of malignancyin myeloid leukaemia. Nature. 1978;274:535-539.
11. Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci U S A. 1980;77:2936-2940.
12. Breitman TR, Collins SJ, Keene BR. Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood. 1981;57:1000-1004.
13. Flynn PJ, Miller WJ, Weisdorf DJ, et al. Retinoic acid treatment of acute promyelocytic leukemia: in vitro and in vivo observations. Blood. 1983;62:1211-1217.
14. Nilsson B. Probable in vivo induction of differentiation by retinoic acid of promyelocytes in acute promyelocytic leukaemia. Br J Haematol. 1984; 57:365-371.
15. Daenen S, Vellenga E, van Dobbenburgh OA, Halie MR. Retinoic acid as antileukemic therapyin apatient with acute promyelocytic leukemia and Aspergillus pneumonia. Blood. 1986;67:559-561.
16. Runde V, Aul C, Sudhoff T, Heyll A, Schneider W. Retinoic acid in the treatment of acute promyelocytic leukemia: inefficacy of the 13-cis isomer and induction of complete remission by the all-trans isomer complicated bythromboembolic events. Ann Hematol. 1992;64:270-272.
17. Huang ME, Ye YC, Chen SR, et al. All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia: report of 6 cases. Chin Med J. (Engl) 1987;100:949-953.
18. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute pro- myelocytic leukemia. Blood. 1988;72:567-572.
19. Degos L, Chomienne C, Daniel MT, et al. Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid. Lancet. 1990; 336:1440-1441.
20. Chen ZX, Xue YQ, Zhang R, et al. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood. 1991;78:1413-1419.
21. Castaigne S, Chomienne C, Daniel MT, et al. All- trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia, I: clinical results. Blood. 1990;76:1704-1709.
22. Wang ZY, Sun GL, Lu JX, et al. Treatment of acute promyelocytic leukemia with all-trans retinoic acid in China. Nouv Rev Fr Hematol. 1990;32:34-36.
23. Warrell RP, Frankel SR, Miller WH, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). New Engl J Med. 1991;324:1385-1393.
24. Fenaux P, Le Deley MC, Castaigne S, et al. Effect of all trans retinoic acid in newly diagnosed acute promyelocytic leukemia: results of a multicenter randomized trial: European APL 91 Group. Blood. 1993;82:3241-3249.
25. Tallman MS, Andersen JW, Schiffer CA, et al. All- trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood. 2002;100:4298-4302.
26. Sun GL, Huang YG, Chang XF, et al. Clinical study of the treatment with all-trans retinoic acid in 544 APL patients. Chin J Hematol. 1992;13:135-137.
27. Bourgeois E, Chevret S, Sanz M, et al. Long-term follow-up of APL treated with ATRA and chemotherapy (CT) including incidence of late relapses and overall toxicity [abstract]. Blood. 2003;102: 140a. Abstract 483.
28. Avvisati G, Petti MC, Lo Cocco F, et al. The Italian way of treating acute promyelocytic leukemia (APL): final act [abstract]. Blood. 2003;102:142a. Abstract 487.
29. Sanz MA, Martin G, Gonzalez M, et al. Risk- adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004;103:1237-1243.
30. Asou N, Kishimoto Y, Kiyoi H, et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RAR{alpha} transcript after consolidation therapy: The Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood. 2007;110:59-66.
31. Ades L, Chevret S, Raffoux E, et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol. 2006;24:5703-5710.
32. de Botton S, Chevret S, Coiteux V, et al. Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial. Leukemia. 2003;17:339-342.
33. Schlenk RF, Germing U, Hartmann F, et al. High- dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia. 2005;19:978-983.
34. Jurcic JG, Nimer SD, Scheinberg DA, et al. Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia. Blood. 2001;98:2651-2656.
35. Gallagher RE, Yeap BY, Bi W, et al. Quantitative realtime RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood. 2003;101:2521-2528.
36. Gu BW, Hu J, Xu L, et al. Feasibility and clinical significance of real-time quantitative RT-PCR assay of PML-RARalpha fusion transcript in patients with acute promyelocytic leukemia. Hematol J. 2001;2:330-340.
37. Iland H, Bradstock K, Chong L, et al. Results of the APML3 trial of ATRA, intensive idarubicin and triple maintenance combined with molecular monitoring in acute promyelocytic leukemia (APL): a study by the Australasian Leukemia and lymphoma Group (ALLG) [abstract]. Blood. 2003; 102:141a. Abstract 484.
38. Jacomo RH, Melo R, Souto F, et al. Clinical features and outcome of 148 patients with acute promyelocytic leukemia in Brazil [abstract]. Blood. 2006;108:Abstract 3326.
39. Ribeiro RC, Rego E. Management of APL in developing countries: epidemiology, challenges and opportunities for international collaboration. Hematol (Am Soc Hematol Educ Program). 2006; 162-168.
40. RowleyJD, Golomb HM, DoughertyC. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet. 1977; 1:549-550.
41. deThé H, Chomienne C, Lanotte M, Degos L Dejean A. The t (15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature. 1990;347:558-561.
42. Kakizuka A, Miller WH Jr, Umesono K, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell. 1991;66:663-674.
43. Lo-Coco F, Ammatuna E. The biology of acute promyelocytic leukemia and its impact on diagnosis and treatment. Hematol (Am Soc Hematol Educ Program). 2006;156-161.
44. He LZ, Guidez F, Tribioli C, et al. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet. 1998;18:126-135.
45. Kelly LM, Kutok JL, Williams IR, et al. PML/ RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci U S A. 2002;99:8283-8288.
46. Chan IT, Kutok JL, Williams IR, et al. Oncogenic K-ras cooperates with PML-RAR alpha to induce an acute promyelocytic leukemia-like disease. Blood. 2006;108:1708-1715.
47. Chen S-J, Zelent A, Tong JH, et al. Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t(11;17)(q23;q21) in a patient with acute promyelocytic leukemia. J Clin Invest. 1993;91:2260-2267.
48. Chen Z, Brand NJ, Chen A, et al. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBOJ. 1993;12:1161-1167.
49. Licht JD, Chomienne C, Goy A, et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood. 1995;85:1083-1094.
50. Redner RL. Variations on a theme: the alternate translocations in APL. Leukemia. 2002;16:1927-1932.
51. Zhou G, Zhang J, Wang Z, Chen S, Chen Z. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy Phil Trans R Soc B. 2007;362:959-971.
52. Cheng GX, Zhu XH, Men XQ, et al. Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promy- elocytic leukemia variant fusion genes PLZF- RARalpha and NPM-RARalpha. Proc Natl Acad Sci USA. 1999;96:6318-6323.
53. Zheng PZ, Wang KK, Zhang QY, et al. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentia- tion/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci USA. 2005;102:7653-7658.
54. Nervi C, Ferrara FF, Fanelli M, et al. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. Blood. 1998;92:2244-2251.
55. Brown D, Kogan S, Lagasse E, et al. APML- RARalpha transgene initiates murine acute pro- myelocytic leukemia. Proc Natl Acad Sci U S A. 1997;94:2551-2556.
56. vom Baur E, Zechel C, Heery D, et al. Differential ligand-dependent interactions between the AF-2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1. EMBO J. 1996;15:110-124.
57. Zhu J, Chen Z, Lallemand-Breitenbach V, de The H. How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer. 2002;2:705-713.
58. Sun HD, Ma L, Hu XC, Zhang TD. Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chin. J Integrat Chin West Med. 1992;12:170-171.
59. Zhang P, Wang SY, Hu LH. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol. 1996;17:58-62.
60. Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996;88:1052-1061.
61. Chen GQ, Shi XG, Tang W, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL), I: As2O3 exerts dose- dependent dual effects on APL cells. Blood. 1997; 89:3345-3353.
62. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL), II: clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89:3354-3360.
63. Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999;94:3315-3324.
64. Mathews V, George B, Lakshmi KM, et al. Single- agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006;107:2627-2632.
65. Carmosino I, Latagliata R, Avvisati G, et al. Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia. Haematologica. 2004;89:615-617.
66. Shigeno K, Naito K, Sahara N, et al. Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postre- mission therapies. Int J Hematol. 2005;82:224- 229.
67. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19:3852-3860.
68. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol. 2006;17:131-134.
69. Wang ZY. Ham-Wasserman lecture: treatment of acute leukemia by inducing differentiation and apoptosis. Hematology (Am Soc Hematol Educ Program). 2003;1-13.
70. Huang SL, Guo AX, Xiang Y, et al. Clinical study on the treatment of acute promyelocytic leukemia with composite Indigo Naturalis tablets. Chin J Hematol. 1995;16:26-28.
71. The Cooperation Group of Phase II. Clinical trial of compound Huangdai tablet: phase II clinical trial of compound Huangdai tablet in newly diagnosed acute promyelocytic leukemia. Chin J Hematol. 2006;27:801-804.
72. Lu DP, Qiu JY, Jiang B, et al. Tetra-arsenic tetra- sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood. 2002;99:3136-3143.
73. Chen Z, Zhao WL, Shen ZX, et al. Arsenic trioxide and acute promyelocytic leukemia: clinical and biological. Curr Top Microbiol Immunol. 2007;313:129-144.
74. Li J, Chen P, Sinogeeva N, et al. Arsenic trioxide promotes histone H3 phosphoacetylation at the chromatin of CASPASE-10 in acute promyelocytic leukemia cells. J Biol Chem. 2002;277:49504-49510.
75. Davison K, Mann KK, Miller WH Jr. Arsenic trioxide: mechanisms of action. Semin Hematol. 2002;39:3-7.
76. Pan XY, Chen GQ, Cai L, Buscemi S, Fu GH. Anion exchanger 2 mediates the action of arsenic trioxide. Br J Haematol. 2006;134:491-499.
77. Bernardini S, Nuccetelli M, Noguera NI, et al. Role of GSTP1-1 in mediating the effect of As2O3 in the acute promyelocytic leukemia cell line NB4. Ann Hematol. 2006;85:681-687.
78. Ninomiya M, Kajiguchi T, Yamamoto K, et al. Increased oxidative DNA products in patients with acute promyelocytic leukemia during arsenic therapy. Haematologica. 2006;91:1571-1572.
79. Chou WC, Chen HY, Yu SL, et al. Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005;106:304-310.
80. Mathieu J, Besancon F. Arsenic trioxide represses NF-kappaB activation and increases apoptosis in ATRA-treated APL cells. Ann NY Acad Sci. 2006;1090:203-208.
81. Glienke W, Chow KU, Bauer N, Bergmann L. Down-regulation of wt1 expression in leukemia cell lines as part of apoptotic effect in arsenic treatment using two compounds. Leuk Lymphoma. 2006;47:1629-1638.
82. Joe Y, Jeong JH, Yang S, et al. ATR, PML, and CHK2 play a role in arsenic trioxide-induced apoptosis. J Biol Chem. 2006;281:28764-28771.
83. Jing Y, Wang L, Xia L, et al. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood. 2001;97:264-269.
84. Lallemand-Breitenbach V, Guillemin MC, Janin A, et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med. 1999; 189:1043-1052.
85. Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2004;101:5328-5335.
86. Liu YF, Zhu YM, Shi ZZ, et al. Long-term follow-up confirms the benefit of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) as front line therapy for newly diagnosed acute promyelocytic leukemia [abstract]. Blood. 2006;108:170a. Abstract 565.
87. Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107:3469-3473.
88. Wang G, Li W, Cui J, et al. An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid. Hematol Oncol. 2004;22:63-71.
89. Pendino F, Flexor M, Delhommeau F, et al. Retinoids down-regulate telomerase and telomere length in a pathway distinct from leukemia cell differentiation. Proc Natl Acad Sci USA. 2001;98:6662-6667.
90. Tarkanyi I, Dudognon C, Hillion J, et al. Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death. Leukemia. 2005;19:1806-1811.
91. Tarrade A, Bastien J, Bruck N, et al. Retinoic acid and arsenic trioxide cooperate for apoptosis through phosphorylated RXR alpha. Oncogene. 2005;24:2277-2288.
92. Zhu J, Lallemand-Breitenbach V, de TH. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. Oncogene. 2001;20:7257-7265.
93. Zhu Q, Zhang JW, Zhu HQ, et al. Synergic effects of arsenic trioxide and cAMP during acute promyelo- cytic leukemia cell maturation subtends a novel signaling cross-talk. Blood. 2002;99:1014-1022.
94. Zhao Q, Tao J, Zhu Q, et al. Rapid induction of cAMP/PKA pathway during retinoic acid-induced acute promyelocytic leukemia cell differentiation. Leukemia. 2004;18:285-292.
95. Leung J, Pang A, Yuen WH, Kwong YL, Tse EWC. Relationship of expression of aquaglycero- porin 9 with arsenic uptake and sensitivity in leukemia cells. Blood. 2007;109:740-746.
96. Lo-Coco F, Cimino G, Breccia M, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood. 2004;104:1995-1999.
97. Jurcic JG, DeBlasio T, Dumont L, Yao TJ, Scheinberg DA. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res. 2000;6:372-380.
98. Kuchenbauer F, Schoch C, Kern W, et al. Impact of FLT3 mutations and promyelocytic leukaemia- breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia. Br J Haematol. 2005;130:196-202.
99. Sohal J, Phan VT, Chan PV, et al. A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood. 2003;101:3188-3197.
100. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451-458.
101. CoreySJ, Locker J, Oliveri DR, et al. Anon-classical translocation involving 17q12 (retinoic acid receptor alpha) in acute promyelocytic leukemia (APML) with atypical features. Leukemia. 1994;8:1350-1353.
102. Wells RA, Hummel JL, De KA, et al. A new variant translocation in acute promyelocytic leukaemia: molecular characterization and clinical correlation. Leukemia. 1996;10:735-740.
103. Arnould C, Philippe C, Bourdon V, et al. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor {alpha} in acute promyelocytic-like leukaemia. Hum Mol Genet. 1999;8:1741-1749.
104. Testi AM, Biondi A, Lo CF, et al. GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood. 2005;106:447-453.
105. Mandelli F, Latagliata R, Avvisati G, et al. Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia: results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. Leukemia. 2003;17:1085-1090.
106. Raelson JV, Nervi C, Rosenauer A, et al. The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood. 1996;88:2826-2832.
107. Zhu J, Gianni M, Kopf E, et al. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. Proc Natl Acad Sci USA. 1999;96:14807-14812.
108. Liu TX, Zhang JW, Tao J, et al. Gene expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemiacells. Blood. 2000;96:1496-1504.
109. Lazo G, Kantarjian H, Estey E, et al. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience. Cancer. 2003;97:2218-2224.
110. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. New Engl J Med. 1998;339:1341-1348.
111. Liu YF, Zhu YM, Shen SH, et al. Molecular response in acute promyelocytic leukemia: a direct comparison of regular and real-time RT-PCR. Leukemia. 2006;20:1393-1399.